Citations

Clear

626 citation(s) found for "Mehta, SH".

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, Patrick Y. , Barboriak, Danial, DeGroot, John, Lassman, Andrew B. , Molinaro, Annette M. , Preusser, Mattias, Rahman, Rifaquat , Shankar, Lalitha , Sul, Joohee, Villanueva‐Meyer, Javier , Macdonald, David , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, Gilbert , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology Advances | August 4, 2023 | Volume: 5 | Issue: Supplement_3 | Pages: iii8-iii8

10.1093/noajnl/vdad070.029 Get It

Abstract The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve the reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and uncertainty emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. Informed by data from a cohort of glioblastoma patients and other evaluations of RANO criteria that allowed evaluation of features of the different criteria, we propose updates to the RANO criteria (RANO 2.0). Based on the 2021 WHO classification of gliomas, we recommend a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the post-radiotherapy MRI, rather than the post-surgical MRI, will be used as the baseline for future comparison. Since the incidence of pseudoprogression is high in the 12 weeks following radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, is required to define tumor progression. However, confirmation scans are not mandatory after this period nor for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is an option. The primary measurement remains the maximum cross-sectional area of tumor (2-dimensional) but volumetric measurements are an option. For IDH-wildtype glioblastoma, the non-enhancing disease will no longer be evaluated. In IDH-mutated tumors with a significant non-enhancing component, clinical trials may require evaluating both the enhancing and non-enhancing tumor components for response assessment.
Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria
Claasen, Marco P. A. W. , Emond, Jean C. , Fox, Alyson N. , Pomposelli, James J. , Tabrizian, Parissa , Mehta, Neil , Emamaullee, Juliet , Genyk, Yuri , Tomiyama, Koji , Sasaki, Kazunari , Hashimoto, Koji , Nagai, Shunji , Olthoff, Kim M. , Taner, Timuçin , Liapakis, AnnMarie , Halazun, Karim J. , (NALLDIG), On behalf of the North American Living Liver Donor Innovation Group, Halazun, Karim J , Ivanics, Tommy , Samstein, Benjamin , Pomfret, Elizabeth , Florman, Sander , Roberts, John P. , Abouljoud, Marwan , Hoteit, Maarouf , Heimbach, Julie K. , Mulligan, David C. , Sapisochín, Gonzalo , (NALLDIG), On behalf of the North American Living Liver Donor Innovation Group

Mayo Clinic

Annals of Surgery | July 31, 2023 | Volume: 279 | Issue: 1 | Pages: 104-111

10.1097/sla.0000000000006049 | PMID 37522174 Get It

Objective: To evaluate long-term oncologic outcomes of patients post–living donor liver transplantation (LDLT) within and outside standard transplantation selection criteria and the added value of the incorporation of the New York-California (NYCA) score. Background: LDLT offers an opportunity to decrease the liver transplantation waitlist, reduce waitlist mortality, and expand selection criteria for patients with hepatocellular carcinoma (HCC). Methods: Primary adult LDLT recipients between October 1999 and August 2019 were identified from a multicenter cohort of 12 North American centers. Posttransplantation and recurrence-free survival were evaluated using the Kaplan-Meier method. Results: Three hundred sixty LDLTs were identified. Patients within Milan criteria (MC) at transplantation had a 1, 5, and 10-year posttransplantation survival of 90.9%, 78.5%, and 64.1% versus outside MC 90.4%, 68.6%, and 57.7% (P = 0.20), respectively. For patients within the University of California San Francisco (UCSF) criteria, respective posttransplantation survival was 90.6%, 77.8%, and 65.0%, versus outside UCSF 92.1%, 63.8%, and 45.8% (P = 0.08). Fifty-three (83%) patients classified as outside MC at transplantation would have been classified as either low or acceptable risk with the NYCA score. These patients had a 5-year overall survival of 72.2%. Similarly, 28(80%) patients classified as outside UCSF at transplantation would have been classified as a low or acceptable risk with a 5-year overall survival of 65.3%. Conclusions: Long-term survival is excellent for patients with HCC undergoing LDLT within and outside selection criteria, exceeding the minimum recommended 5-year rate of 60% proposed by consensus guidelines. The NYCA categorization offers insight into identifying a substantial proportion of patients with HCC outside the MC and the UCSF criteria who still achieve similar post-LDLT outcomes as patients within the criteria.
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
Russler‐Germain, David A. , Krysiak, Kilannin , Ramirez, Cody A. , Watkins, Marcus P. , Gomez, Felicia , Trani, Lee , Geyer, Susan M. , Cashen, Amanda F. , Mehta–Shah, Neha , Alderuccio, Juan Pablo , Lossos, Izidore S. , Ondrejka, Sarah L. , Leonard, John P. , Griffith, Malachi , Griffith, Obi L. , Fehniger, Todd A. , Ramirez, Cody , Watkins, Marcus , Gomez, Felicia , Mehta-Shah, Neha , Kahl, Brad S , Bartlett, Nancy L , Alderuccio, Juan Pablo , Lossos, Izidore S , Ondrejka, Sarah , Hsi, Eric D , Griffith, Obi L , Fehniger, Todd A , Krysiak, Kilannin , Griffith, Malachi , Russler-Germain, David A , Mosior, Matthew , Skidmore, Zachary L. , Gao, Feng , Kahl, Brad S. , Bartlett, Nancy L. , Hsi, Eric D. , Martin, Peter

Mayo Clinic

Blood Advances | July 26, 2023 | Volume: 7 | Issue: 18 | Pages: 5524-5539

10.1182/bloodadvances.2023010779 | PMID 37493986 Get It

Abstract Follicular lymphoma (FL) is clinically heterogeneous, with select patients tolerating extended watch-and-wait, whereas others require prompt treatment, suffer progression of disease within 24 months of treatment (POD24), and/or experience aggressive histologic transformation (t-FL). Because our understanding of the relationship between genetic alterations in FL and patient outcomes remains limited, we conducted a clinicogenomic analysis of 370 patients with FL or t-FL (from Cancer and Leukemia Group B/Alliance trials 50402/50701/50803, or real-world cohorts from Washington University School of Medicine, Cleveland Clinic, or University of Miami). FL subsets by grade, stage, watch-and-wait, or POD24 status did not differ by mutation burden, whereas mutation burden was significantly higher in relapsed/refractory (rel/ref) FL and t-FL than in newly diagnosed (dx) FL. Nonetheless, mutation burden in dx FL was not associated with frontline progression-free survival (PFS). CREBBP was the only gene more commonly mutated in FL than in t-FL yet mutated CREBBP was associated with shorter frontline PFS in FL. Mutations in 20 genes were more common in rel/ref FL or t-FL than in dx FL, including 6 significantly mutated genes (SMGs): STAT6, TP53, IGLL5, B2M, SOCS1, and MYD88. We defined a mutations associated with progression (MAP) signature as ≥2 mutations in these 7 genes (6 rel/ref FL or t-FL SMGs plus CREBBP). Patients with dx FL possessing a MAP signature had shorter frontline PFS, revealing a 7-gene set offering insight into FL progression risk potentially more generalizable than the m7–Follicular Lymphoma International Prognostic Index (m7-FLIPI), which had modest prognostic value in our cohort. Future studies are warranted to validate the poor prognosis associated with a MAP signature in dx FL, potentially facilitating novel trials specifically in this high-risk subset of patients.
Catheter Ablation of Atrial Fibrillation in Adult Congenital Heart Disease: Procedural Characteristics and Outcomes
Hu, Tiffany , Janga, Chaitra , Amin, Mustapha, Tan, Nicholas Y. , Hodge, David O. , Mehta, Ramila A. , McLeod, Christopher J. , Chiriac, Anca , Miranda, William R. , Connolly, Heidi M. , Asirvatham, Samuel J. , Deshmukh, Abhishek , Egbe, Alexander C. , Madhavan, Malini , Hu, Tiffany Y , Deshmukh, Abhishek J , Asirvatham, Samuel J , McLeod, Christopher J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 24, 2023 | Volume: 16 | Issue: 8 | Pages: 437-446

10.1161/circep.122.011392 | PMID 37485717 Get It

BACKGROUND: The outcomes of catheter ablation for atrial fibrillation in adults with congenital heart disease are not well described. METHODS: In a retrospective study of adult patients with congenital heart disease who underwent catheter ablation for atrial fibrillation between 2000 and 2020 at Mayo Clinic, procedural characteristics and outcomes were collected. The primary outcomes were atrial arrhythmia (AA) recurrence following a 3-month blanking period and repeat ablation. An arrhythmia clinical severity score was assessed pre- and post-ablation based on the duration of arrhythmia episodes, symptoms, cardioversion frequency, and antiarrhythmic drug use. RESULTS: One hundred forty-five patients (age, 57±12 years; 28% female; 63% paroxysmal atrial fibrillation) underwent 198 ablations with a median follow-up of 26 months (interquartile range, 14–69). One hundred ten, 26, and 9 patients had simple, moderate, and complex congenital heart disease, respectively. All patients underwent pulmonary vein isolation, and non–pulmonary vein targets were ablated in 79 (54%). AA recurrence at 12 months was 37% (95% CI, 29%–45%). On univariate analysis, increasing left atrial volume index was associated with higher odds of AA recurrence (odds ratio, 1.03 [1.00–1.06] per 1 mL/m 2 increment; P =0.05). Noninducibility of atrial flutter was predictive of decreased odds of AA recurrence (odds ratio, 0.43 [0.21–0.90]; P =0.03). A second ablation was performed in 43 patients after a median of 20 (interquartile range, 8–37) months. Arrhythmia clinical severity scores improved following ablation, reflecting a decrease in symptoms, cardioversions, and antiarrhythmic drugs. CONCLUSIONS: Catheter ablation of atrial fibrillation is feasible and effective in patients with adult congenital heart disease and reduces symptoms. Recurrence of AA frequently requires repeat ablation.
Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort
Choudhury, Parichita , Belden, Christine M. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Shill, Holly A. , Beach, Thomas G. , Driver-Dunckley, Erika, Choudhury, Parichita , Zhang, Nan , Adler, Charles H. , Chen, Kewei , Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | July 8, 2023 | Volume: 19 | Issue: 10 | Pages: 4377-4387

10.1002/alz.13357 | PMID 37422286 Get It

Abstract INTRODUCTION We examined the progression of extrapyramidal symptoms and signs in autopsy‐confirmed dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and Alzheimer's disease dementia (AD). METHODS Longitudinal data were obtained from Arizona Study of Aging and Neurodegenerative Disease, with PDD ( n = 98), AD ( n = 47) and DLB ( n = 48) further sub‐grouped as with or without parkinsonism (DLB+ and DLB−). Within‐group Unified Parkinson's Disease Rating Scale (UPDRS) ‐II and UPDRS‐III trajectories were analyzed using non‐linear mixed effects models. RESULTS In DLB, 65.6% had parkinsonism. Baseline UPDRS‐II and III scores (off‐stage) were highest ( P < 0.001) for PDD (mean ± SD 14.3 ± 7.8 and 27.4 ± 16.3), followed by DLB+ (6.0 ± 8.8 and 17.2 ± 17.1), DLB− (1.1 ± 1.3 and 3.3 ± 5.5) and AD (3.2 ± 6.1 and 8.2 ± 13.6). Compared to PDD, the DLB+ group had faster UPDRS‐III progression over 8‐years (Cohen's‐ d range 0.98 to 2.79, P < 0.001), driven by gait ( P < 0.001) and limb bradykinesia ( P = 0.02) subscales. DISCUSSION Motor deficits progress faster in DLB+ than PDD, providing insights about expected changes in motor function. Highlights Dementia with Lewy bodies has faster motor progression than Parkinson's disease dementia Linear and non‐linear mixed modeling analysis of longitudinal data was utilized Findings have implications for clinical prognostication and trial design
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Streck, Joanna M. , Lee, Ju‐Whei , Walter, Angela Wangari , Rosen, Rachel , Gareen, Ilana F. , Kircher, Sheetal Mehta , Herman, B. , Carlos, Ruth C. , Kumar, Shaji , Mayer, Ingrid A. , Fenske, Timothy S. , Neal, Joel W. , Hodi, F. Stephen , Kyriakopoulos, Christos E. , Tempany, Clare M. , Shanafelt, Tait D. , Mayer, IA , Rosen, Rachel L , Herman, Benjamin A , Saba, Nabil F , Fenske, Timothy S , Neal, Joel W , Atkins, Michael B. , Hodi, Frank Stephen , Kyriakopoulos, Christos E , Tempany, Clare , Shanafelt, Tait D , Wagner, Lynne , Land, Stephanie R , Park, Elyse R , Ostroff, Jamie S , Saba, Nabil F. , Wagner, Lynne I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 6, 2023 | Volume: 32 | Issue: 11 | Pages: 1552-1557

10.1158/1055-9965.epi-23-0420 | PMID 37410096 Get It

Abstract Background: While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known about ATP use patterns in cancer survivors enrolled in clinical trials. We investigated prevalence of tobacco product use, and factors associated with past 30-day use, among patients with cancer in national trials. Methods: Cancer survivors (N = 756) enrolled in 9 ECOG-ACRIN clinical trials (2017–2021) completed a modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) which assessed baseline cigarette and ATP use since cancer diagnosis and in the past 30 days. Results: Patients were on average 59 years old, 70% male, and the mean time since cancer diagnosis was 26 months. Since diagnosis, cigarettes (21%) were the most common tobacco product used, followed by smokeless tobacco use (5%), cigars (4%), and e-cigarettes (2%). In the past 30 days, 12% of patients reported smoking cigarettes, 4% cigars, 4% using smokeless tobacco, and 2% e-cigarettes. Since cancer diagnosis, 5.5% of the sample reported multiple tobacco product use, and 3.0% reported multiple product use in the past 30 days. Males (vs. females; OR 4.33; P = 0 &lt; 0.01) and individuals not living with another person who smokes (vs. living with; OR, 8.07; P = 0 &lt; 0.01) were more likely to use ATPs only versus cigarettes only in the past 30 days. Conclusions: Among patients with cancer, cigarettes were the most prevalent tobacco product reported. Impact: Regardless, ATPs and multiple tobacco product use should be routinely assessed in cancer care settings.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Coveler, Andrew L. , Smith, David C. , Curti, Brendan D. , Goel, Sanjay , Kuzel, Timothy M. , Rixe, Olivier , Bajor, David L. , Gutierrez, Martin , Lee, Hun Ju , Heath, Elisabeth I. , Thompson, John A. , Ansari, Sahar , Jacquemont, Céline, Topletz‐Erickson, Ariel R. , Zhou, Peigen , Curti, Brendan , Goel, Sanjay , Phillips, Tycel , Mehta, Amitkumar , Markovic, Svetomir N. , Gajewski, Thomas Frank , Gopal, Ajay K. , Caimi, Paolo F. , Ansari, Sahar, Schmitt, Michael W. , Grilley‐Olson, Juneko E.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 29, 2023 | Volume: 11 | Issue: 6 | Pages: e005584

10.1136/jitc-2022-005584 | PMID 37385724 Get It

Background SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, possibly enabling greater immune stimulation than other CD40 agonists. A first-in-human phase 1 trial was conducted to examine safety, pharmacokinetics, and pharmacodynamics of SEA-CD40 monotherapy in patients with advanced solid tumors and lymphoma. Methods SEA-CD40 was administered intravenously to patients with solid tumors or lymphoma in 21-day cycles with standard 3+3 dose escalation at 0.6, 3, 10, 30, 45, and 60 µg/kg. An intensified dosing regimen was also studied. The primary objectives of the study were to evaluate the safety and tolerability and identify the maximum tolerated dose of SEA-CD40. Secondary objectives included evaluation of the pharmacokinetic parameters, antitherapeutic antibodies, pharmacodynamic effects and biomarker response, and antitumor activity. Results A total of 67 patients received SEA-CD40 including 56 patients with solid tumors and 11 patients with lymphoma. A manageable safety profile was observed, with predominant adverse events of infusion/hypersensitivity reactions (IHRs) reported in 73% of patients. IHRs were primarily ≤grade 2 with an incidence associated with infusion rate. To mitigate IHRs, a standardized infusion approach was implemented with routine premedication and a slowed infusion rate. SEA-CD40 infusion resulted in potent immune activation, illustrated by dose dependent cytokine induction with associated activation and trafficking of innate and adaptive immune cells. Results suggested that doses of 10–30 µg/kg may result in optimal immune activation. SEA-CD40 monotherapy exhibited evidence of antitumor activity, with a partial response in a patient with basal cell carcinoma and a complete response in a patient with follicular lymphoma. Conclusions SEA-CD40 was tolerable as monotherapy and induced potent dose dependent immune cell activation and trafficking consistent with immune activation. Evidence of monotherapy antitumor activity was observed in patients with solid tumors and lymphoma. Further evaluation of SEA-CD40 is warranted, potentially as a component of a combination regimen. Trial registration number NCT02376699.
Palliative Care Education in US Physical Medicine and Rehabilitation Residency Programs: Current Practices, Perceived Needs, and Barriers
Yeh, Jonathan C. , Ambady, Leena, Lewis, Ryan, Mehta, Ambereen K. , Asher, Arash , Engle, Jessica , Lewis, Ryan, Raj, Vishwa S.

Mayo Clinic

Journal of Palliative Medicine | June 19, 2023 | Volume: 26 | Issue: 8 | Pages: 1128-1132

10.1089/jpm.2022.0606 | PMID 37335750 Get It

Abstract 14283: Influence of the HEAR Score for 30-day Risk-Stratification in Emergency Department Patients Evaluated With High-Sensitivity Cardiac Troponin T
Ola, Olatunde , Akula, Ashok , Knott, Jonathan D , Mehta, Ramila A. , Hodge, David O. , Gulati, Rajiv , Jaffe, Allan S. , Sandoval, Yader , Michieli, Laura De , Jaffe, Allan S.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.14283 Get It

Background: The 2021 ACC/AHA chest pain guidelines recommend risk scores such as HEAR (History, Electrocardiogram, Age, Risk Factors) for short term risk-stratification yet limited data exists integrating them with high-sensitivity cardiac troponin T (hs-cTnT). Methods: Retrospective, multicenter (n=2), observational, U.S. cohort study of consecutive ED patients without ST-elevation myocardial infarction (MI) who had at least one hs-cTnT (limit of quantitation, LoQ, <6 ng/L, and sex-specific 99 th percentiles of 10 ng/L for women and 15 ng/L for men) measurement on clinical indication in whom HEAR scores (0-8) were calculated. The composite major adverse cardiovascular (MACE) outcome was 30-day MI and death. Results: Among 1,979 ED patients undergoing hs-cTnT measurement, 1045 (53%) were classified as low-risk (0-3), 914 (46%) as intermediate-risk (4-6), and 20 (1%) as high-risk (7-8) based on HEAR scores. HEAR scores were not associated with an increased risk of 30-day MACE after adjusted analyses. Outcomes according to risk-strata based on HEAR scores and baseline hs-cTnT are shown in Table 1. Patients with quantifiable hs-cTnT (LoQ-99 th ) had an increased risk for 30-day MACE (3.4%) despite being estimated to be low-risk (0-3) per HEAR scores. Conversely, those with serial hs-cTnT<99 th percentile remained at low-risk (range 0% to 1.2%) for 30-day MACE across HEAR score strata. Conclusions: HEAR scores are of limited value in those with baseline hs-cTnT<LoQ or hs-cTnT>99 th percentile where hs-cTnT identifies very low and high-risk patients irrespective of HEAR scores. In those with baseline quantifiable hs-cTnT within the reference range (<99 th percentile), a higher risk (>1%) for 30-day MACE exists even in those with low HEAR scores. With serial hs-cTnT measurements, HEAR scores overestimate risk when hs-cTnT remains <99 th percentile.
Abstract 14136: Diagnosis and Prognosis of Type 2 Myocardial Infarction Using Objective Evidence of Myocardial Ischemia
Knott, Jonathan D , Ola, Olatunde , Akula, Ashok , Mehta, Ramila A. , Hodge, David O. , Gulati, Rajiv , Jaffe, Allan S. , Sandoval, Yader , Michieli, Laura De , Jaffe, Allan S.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.14136 Get It

Introduction: Differentiating type 2 myocardial infarction (T2MI) from myocardial injury can be difficult. The presence of objective evidence of acute myocardial ischemia may facilitate the identification of high-risk T2MI patients. Methods: Retrospective, observational cohort post-hoc analysis of adult emergency department patients undergoing hs-cTnT measurement. Patients with ≥1 hs-cTnT>99th percentile were adjudicated following the Fourth Universal Definition of MI. Patients were categorized as “subjective T2MI” when ischemic symptoms were the lone criteria supporting T2MI, or “objective T2MI” when there was ≥1 objective clinical feature (electrocardiography, imaging, angiography) of acute myocardial ischemia. The primary outcome was mortality. Results: A total of 857 patients were included, amongst which 55 (6.4%) were classified as subjective T2MI, 36 (4.2%) as objective T2MI, and 702 (82%) as myocardial injury. Among objective T2MIs, the most common criteria were ischemic electrocardiographic changes (n=29). Median (IQR) maximum hs-cTnT were 24 (18, 43) ng/L in myocardial injury, 34 (19, 80) in subjective T2MI, and 74 (35, 237) in objective T2MI. Those with objective T2MI had a higher risk of mortality during the index presentation (17% vs. 1.7%, p<0.0001; HR 11.1 95% CI 3.7-33.4) and at 2-year follow-up (47% vs. 31%, p=0.04; HR 1.92, 95% CI 1.17-3.14) than those with myocardial injury (Figure). Objective T2MI had a higher mortality than subjective T2MI at index presentation (17% vs. 2.0%, p=0.01) and at 1- (25% vs. 9.1%, p=0.04) and 3-months (31% vs. 13%, p=0.04) follow-up. There were no mortality differences between subjective T2MI and myocardial injury. Conclusions: In patients diagnosed with T2MI, those with objective evidence of myocardial ischemia have significantly worse outcomes compared to those with myocardial injury and subjective T2MI. A more rigorous definition of T2MI might be a more effective way to define this important entity.